New ICH Guideline Q14 On Analytical Procedure Development – Implications For Gonadotropin API Manufacturers

ICH has finalized the Q14 guideline, which tightens requirements on analytical method development, impurity characterization and validation for urinary gonadotropin APIs including HCG, HMG and urokinase. Crude and intermediate suppliers shall provide more detailed analytical data to downstream formulators. Early compliance with Q14 will become a core competitive advantage for manufacturers targeting regulated global markets.